Cerebrolysin and Aquaporin 4 Inhibition Improve Pathological and Motor Recovery after Ischemic Stroke.

Catalin B, Rogoveanu OC, Pirici I, Balseanu TA, Stan A, Tudorica V, Balea M, Mindrila I, Albu CV, Mohamed G, Pirici D, Muresanu DF

CNS & neurological disorders drug targets1 Jan 2018Cited by 24 (Europe PMC)

PMID29692268DOI10.2174/1871527317666180425124340PepBankPUB-29692268

Publisher page PubMedAsk about this study

Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone5

In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Cerebrolysin.

01AnimalNot a test of Cerebrolysin aloneAnimal study (in vivo)Efficacy outcome
In rats with ischemia, Cerebrolysin with TGN-020 improved motor function preservation.
In plain wordsIn rats with ischemia, Cerebrolysin with TGN-020 improved motor function preservation.
Peptide
Cerebrolysin
Outcome
IncreaseMotor function preservation
Study
ratn: not reported in source
permanent medial cerebral artery occlusion
Outcome group
Exercise and physical function · Nervous system and cognition
Source sentences
Summary
We showed first that the combination treatment animals have a better motor function preservation at seven days after permanent ischemia.
1 context sentence(design, population, supporting numbers)
Summary · context
Using a permanent medial cerebral artery occlusion rat model, we administrated a single dose of the AQP4 inhibitor TGN-020 (100 mg/kg) at 15 minutes after ischemia followed by daily Cerebrolysin dosing (5ml/kg) for seven days.
In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cerebrolysin.
Report a problemFND-2969226801
02AnimalNot a test of Cerebrolysin aloneAnimal study (in vivo)Efficacy outcome
In rats with ischemia, Cerebrolysin with TGN-020 reduced astrocyte scarring compared with Cerebrolysin alone.
In plain wordsIn rats with ischemia, Cerebrolysin with TGN-020 reduced astrocyte scarring compared with Cerebrolysin alone.
Peptide
Cerebrolysin
Outcome
DecreaseAstrocyte scarring
Study
ratn: not reported in source
permanent medial cerebral artery occlusion
Comparator
Cerebrolysin alone
Outcome group
Neuroprotection · Nervous system and cognition
Source sentences
Summary
We have also identified distinct cellular contributions that represent the bases of behavior testing, such as less astrocyte scarring and a larger neuronalsurvival phenotype rate in animals treated with both compounds than in animals treated with Cerebrolysin alone or untreated animals.
1 context sentence(design, population, supporting numbers)
Summary · context
Using a permanent medial cerebral artery occlusion rat model, we administrated a single dose of the AQP4 inhibitor TGN-020 (100 mg/kg) at 15 minutes after ischemia followed by daily Cerebrolysin dosing (5ml/kg) for seven days.
In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cerebrolysin.
Report a problemFND-2969226802
03AnimalNot a test of Cerebrolysin aloneAnimal study (in vivo)Efficacy outcome
In rats with ischemia, Cerebrolysin with TGN-020 reduced astrocyte scarring compared with untreated animals.
In plain wordsIn rats with ischemia, Cerebrolysin with TGN-020 reduced astrocyte scarring compared with untreated animals.
Peptide
Cerebrolysin
Outcome
DecreaseAstrocyte scarring
Study
ratn: not reported in source
permanent medial cerebral artery occlusion
Comparator
Untreated animals
Outcome group
Neuroprotection · Nervous system and cognition
Source sentences
Summary
We have also identified distinct cellular contributions that represent the bases of behavior testing, such as less astrocyte scarring and a larger neuronalsurvival phenotype rate in animals treated with both compounds than in animals treated with Cerebrolysin alone or untreated animals.
1 context sentence(design, population, supporting numbers)
Summary · context
Using a permanent medial cerebral artery occlusion rat model, we administrated a single dose of the AQP4 inhibitor TGN-020 (100 mg/kg) at 15 minutes after ischemia followed by daily Cerebrolysin dosing (5ml/kg) for seven days.
In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cerebrolysin.
Report a problemFND-2969226803
04AnimalNot a test of Cerebrolysin aloneAnimal study (in vivo)Efficacy outcome
In rats with ischemia, Cerebrolysin with TGN-020 increased neuronal survival phenotype rate compared with Cerebrolysin alone.
In plain wordsIn rats with ischemia, Cerebrolysin with TGN-020 increased neuronal survival compared with Cerebrolysin alone.
Peptide
Cerebrolysin
Outcome
IncreaseNeuronal survival phenotype rate
Study
ratn: not reported in source
permanent medial cerebral artery occlusion
Comparator
Cerebrolysin alone
Outcome group
Neuroprotection · Nervous system and cognition
Source sentences
Summary
We have also identified distinct cellular contributions that represent the bases of behavior testing, such as less astrocyte scarring and a larger neuronalsurvival phenotype rate in animals treated with both compounds than in animals treated with Cerebrolysin alone or untreated animals.
1 context sentence(design, population, supporting numbers)
Summary · context
Using a permanent medial cerebral artery occlusion rat model, we administrated a single dose of the AQP4 inhibitor TGN-020 (100 mg/kg) at 15 minutes after ischemia followed by daily Cerebrolysin dosing (5ml/kg) for seven days.
In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cerebrolysin.
Report a problemFND-2969226804
05AnimalNot a test of Cerebrolysin aloneAnimal study (in vivo)Efficacy outcome
In rats with ischemia, Cerebrolysin with TGN-020 increased neuronal survival phenotype rate compared with untreated animals.
In plain wordsIn rats with ischemia, Cerebrolysin with TGN-020 increased neuronal survival compared with untreated animals.
Peptide
Cerebrolysin
Outcome
IncreaseNeuronal survival phenotype rate
Study
ratn: not reported in source
permanent medial cerebral artery occlusion
Comparator
Untreated animals
Outcome group
Neuroprotection · Nervous system and cognition
Source sentences
Summary
We have also identified distinct cellular contributions that represent the bases of behavior testing, such as less astrocyte scarring and a larger neuronalsurvival phenotype rate in animals treated with both compounds than in animals treated with Cerebrolysin alone or untreated animals.
1 context sentence(design, population, supporting numbers)
Summary · context
Using a permanent medial cerebral artery occlusion rat model, we administrated a single dose of the AQP4 inhibitor TGN-020 (100 mg/kg) at 15 minutes after ischemia followed by daily Cerebrolysin dosing (5ml/kg) for seven days.
In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cerebrolysin.
Report a problemFND-2969226805

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
14 Oct 2026, 05:02 UTC
Study results updated
Version 1
14 Oct 2026, 01:46 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.